Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
about
Assessment of pancreatic β-cell function: review of methods and clinical applicationsThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaThe Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic ReviewComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic reviewExenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SEffect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-AnalysisSafety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trialsEfficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisRandomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).Evolution of exenatide as a diabetes therapeutic.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisEfficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III studyExenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
P2860
Q26829445-D7B9DB13-938D-4550-82BB-85DDC3E9FCF8Q26852590-B0877D91-E8AC-4DA9-8010-81E9000C166AQ28078225-895200D7-8565-4A32-ABC6-C20024B4431AQ28540671-F115A22C-4C26-4596-8243-0B936F0AF3A9Q30558739-B98CCFC8-6B23-43F6-B547-B9CEBB6D6169Q31066859-CE7F0218-D62C-4FAA-8454-04F9E1B2C778Q33585566-5A756B56-A8CB-46C1-A688-D77037423E34Q33603466-A164DCDC-5A85-47E2-9578-01BD5DC806F6Q35035176-FAE18B9E-82F5-4926-87CD-D60E33E5FDD7Q35192193-3E1924A8-08F5-42A2-9CB0-76994C7D3C9DQ35223375-2EB03EFD-BA29-45FC-9B8A-88592CAD0DC5Q35677315-314ADC05-5B74-4ED6-9DC4-3175135CAB6FQ35780935-DDCEAD32-DB4A-49A5-839E-4858203D0F6CQ36011993-3DCB6485-3BCA-464F-9FA3-B6718B2B6F4DQ36303786-1D12BB6D-CE0B-4EF9-A8F8-2B3064348451Q36877205-58F87C5D-BA3E-4762-BB12-CCB8623AB668Q37030680-405DD39F-1A09-4306-BE3E-FE1420BBA2CCQ37295993-A4806317-375B-464B-9ED1-B2AB4252FF7DQ37295997-3A20D572-4AE2-4171-947C-D93F346AF946Q37670111-23F55599-163B-4DED-B026-60C0D09F6E06Q38179267-DC5D0A97-32FD-41AB-948D-EB21EDFF383DQ38198185-974B1933-9FB7-4E66-ADA7-42C00ADD8E6FQ38749391-FCA39F82-8286-4736-8F57-A9B2D5E80FBCQ39553746-8F08F362-6CD5-403A-B5E6-4468810E6A1FQ47169468-8CD88E6B-69F4-4A1D-8A7C-6977E8D3413FQ49526609-B1FAA775-C633-4D70-ACBC-5C23F2E6D553
P2860
Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@ast
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@en
Improved glycemic control and ...... type 2 diabetes over 24 weeks.
@nl
type
label
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@ast
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@en
Improved glycemic control and ...... type 2 diabetes over 24 weeks.
@nl
prefLabel
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@ast
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@en
Improved glycemic control and ...... type 2 diabetes over 24 weeks.
@nl
P2093
P2860
P1476
Improved glycemic control and ...... type 2 diabetes over 24 weeks
@en
P2093
Ayuko Yamamura
Hideaki Sowa
Marilyn K Boardman
Mitsuyoshi Namba
Takashi Kadowaki
Takeshi Imaoka
Wakana Goto
P2860
P304
P356
10.1111/J.2040-1124.2010.00084.X
P577
2011-06-01T00:00:00Z